Axovant Sciences Ltd. (NYSE:AXON) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Tuesday.

According to Zacks, “Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer’s disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda. “

AXON has been the subject of a number of other reports. Oppenheimer Holdings, Inc. upped their price target on Axovant Sciences from $30.00 to $33.00 and gave the company a “neutral” rating in a research note on Monday, April 17th. CIBC upped their price target on Axovant Sciences from $26.00 to $30.00 and gave the company an “outperform” rating in a research note on Wednesday, June 14th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $31.00 price target on shares of Axovant Sciences in a research note on Tuesday, April 18th. Cowen and Company reaffirmed an “outperform” rating and issued a $30.00 price target (up from $22.00) on shares of Axovant Sciences in a research note on Tuesday, June 13th. Finally, BidaskClub raised Axovant Sciences from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company. Axovant Sciences presently has a consensus rating of “Buy” and a consensus target price of $28.50.

Shares of Axovant Sciences (AXON) traded down 0.05% on Tuesday, hitting $22.09. 778,506 shares of the company’s stock traded hands. Axovant Sciences has a 1-year low of $11.01 and a 1-year high of $25.18. The company’s market cap is $2.37 billion. The firm’s 50-day moving average price is $22.40 and its 200 day moving average price is $17.00.

Axovant Sciences (NYSE:AXON) last announced its quarterly earnings results on Tuesday, June 13th. The biotechnology company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by $0.02. On average, equities research analysts expect that Axovant Sciences will post ($2.24) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Axovant Sciences Ltd. (AXON) Rating Lowered to Sell at Zacks Investment Research” was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/11/axovant-sciences-ltd-axon-rating-lowered-to-sell-at-zacks-investment-research.html.

In other news, Director W Anthony Vernon purchased 53,937 shares of Axovant Sciences stock in a transaction on Monday, April 17th. The stock was purchased at an average price of $18.54 per share, with a total value of $999,991.98. Following the transaction, the director now directly owns 53,937 shares in the company, valued at approximately $999,991.98. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider David Hung purchased 539,375 shares of Axovant Sciences stock in a transaction on Monday, April 17th. The shares were purchased at an average cost of $18.54 per share, with a total value of $10,000,012.50. Following the transaction, the insider now owns 539,375 shares in the company, valued at $10,000,012.50. The disclosure for this purchase can be found here. Corporate insiders own 3.10% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in AXON. Fox Run Management L.L.C. purchased a new position in Axovant Sciences during the second quarter worth $404,000. Point72 Asset Management L.P. increased its position in Axovant Sciences by 1,718.3% in the first quarter. Point72 Asset Management L.P. now owns 209,100 shares of the biotechnology company’s stock worth $3,124,000 after buying an additional 197,600 shares during the period. Bank of America Corp DE increased its position in Axovant Sciences by 38.9% in the first quarter. Bank of America Corp DE now owns 7,396 shares of the biotechnology company’s stock worth $111,000 after buying an additional 2,072 shares during the period. Oppenheimer & Co. Inc. purchased a new position in Axovant Sciences during the first quarter worth $219,000. Finally, Primecap Management Co. CA increased its position in Axovant Sciences by 300.1% in the first quarter. Primecap Management Co. CA now owns 2,878,930 shares of the biotechnology company’s stock worth $43,011,000 after buying an additional 2,159,428 shares during the period. 94.52% of the stock is owned by hedge funds and other institutional investors.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Get a free copy of the Zacks research report on Axovant Sciences (AXON)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Axovant Sciences (NYSE:AXON)

Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.